Elizabeth D Ballard1, Cristan A Farmer2, Jessica Gerner2, Bartholt Bloomfield-Clagett2, Lawrence T Park2, Carlos A Zarate2. 1. Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, United States of America. Electronic address: Elizabeth.Ballard@nih.gov. 2. Experimental Therapeutics & Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, United States of America.
Abstract
BACKGROUND: Early markers preceding suicide ideation (SI) may provide valuable information for both assessment and treatment. The glutamatergic modulator ketamine has rapid, transient effects on SI, creating an opportunity to observe potential antecedents of the re-emergence of SI. This analysis evaluated whether the interaction between two suicide risk factors-psychological pain and hopelessness-were prospectively associated with SI post-ketamine administration. METHODS: Data were drawn from three ketamine clinical trials of participants with treatment-resistant major depressive disorder or bipolar disorder (n = 108) with short- and/or long-term follow-up (three or 11 days). A random intercept cross-lagged panel model evaluated the longitudinal relationship between the correlated concepts, specifically whether the interaction between hopelessness and psychological pain was associated with future SI. RESULTS: Psychological pain and hopelessness were not prospectively associated with SI in short-term or long-term analyses; rather, long-term analyses found that SI was associated with later psychological pain and hopelessness. Similarly, no relationship was observed for other suicide risk factors, including anhedonia, depressed mood, and impaired sleep. LIMITATIONS: Secondary analysis of clinical trial data not collected for this purpose; hopelessness and psychological pain were assessed via proxy measures from existing depression rating scales; the small sample size required a restricted statistical model. CONCLUSIONS: Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine. These results may be due to limited variability in the data. The re-emergence of SI post-ketamine may also not follow patterns typically seen in non-pharmacologic contexts. Individuals with a history of SI warrant careful monitoring post-ketamine administration. Published by Elsevier B.V.
BACKGROUND: Early markers preceding suicide ideation (SI) may provide valuable information for both assessment and treatment. The glutamatergic modulator ketamine has rapid, transient effects on SI, creating an opportunity to observe potential antecedents of the re-emergence of SI. This analysis evaluated whether the interaction between two suicide risk factors-psychological pain and hopelessness-were prospectively associated with SI post-ketamine administration. METHODS: Data were drawn from three ketamine clinical trials of participants with treatment-resistant major depressive disorder or bipolar disorder (n = 108) with short- and/or long-term follow-up (three or 11 days). A random intercept cross-lagged panel model evaluated the longitudinal relationship between the correlated concepts, specifically whether the interaction between hopelessness and psychological pain was associated with future SI. RESULTS: Psychological pain and hopelessness were not prospectively associated with SI in short-term or long-term analyses; rather, long-term analyses found that SI was associated with later psychological pain and hopelessness. Similarly, no relationship was observed for other suicide risk factors, including anhedonia, depressed mood, and impaired sleep. LIMITATIONS: Secondary analysis of clinical trial data not collected for this purpose; hopelessness and psychological pain were assessed via proxy measures from existing depression rating scales; the small sample size required a restricted statistical model. CONCLUSIONS: Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine. These results may be due to limited variability in the data. The re-emergence of SI post-ketamine may also not follow patterns typically seen in non-pharmacologic contexts. Individuals with a history of SI warrant careful monitoring post-ketamine administration. Published by Elsevier B.V.
Authors: Elizabeth D Ballard; Kathleen Wills; Níall Lally; Erica M Richards; David A Luckenbaugh; Tessa Walls; Rezvan Ameli; Mark J Niciu; Nancy E Brutsche; Lawrence Park; Carlos A Zarate Journal: J Affect Disord Date: 2017-04-25 Impact factor: 4.839
Authors: Joseph C Franklin; Jessica D Ribeiro; Kathryn R Fox; Kate H Bentley; Evan M Kleiman; Xieyining Huang; Katherine M Musacchio; Adam C Jaroszewski; Bernard P Chang; Matthew K Nock Journal: Psychol Bull Date: 2016-11-14 Impact factor: 17.737
Authors: Nancy Diazgranados; Lobna Ibrahim; Nancy E Brutsche; Andrew Newberg; Phillip Kronstein; Sami Khalife; William A Kammerer; Zenaide Quezado; David A Luckenbaugh; Giacomo Salvadore; Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate Journal: Arch Gen Psychiatry Date: 2010-08
Authors: Michael F Grunebaum; Hanga C Galfalvy; Tse-Hwei Choo; John G Keilp; Vivek K Moitra; Michelle S Parris; Julia E Marver; Ainsley K Burke; Matthew S Milak; M Elizabeth Sublette; Maria A Oquendo; J John Mann Journal: Am J Psychiatry Date: 2017-12-05 Impact factor: 18.112